Valerio Therapeutics Société anonyme (EPA:ALVIO)
France flag France · Delayed Price · Currency is EUR
0.0540
0.00 (0.00%)
Jul 17, 2025, 5:21 PM CET

Valerio Therapeutics Société anonyme Company Description

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops novel and first-in-class DNA-decoy therapies targeting proteins in tumors and inflammatory disease processes.

The company develops developing VIO-01, which is in Phase 1/2 of the VIO-01 clinical study, a Pan-DDR DNA decoy targeting multiple proteins and repair pathways in preclinical development; and PlatON, generates DecoyTAC combining DNA decoy molecules capable of cell penetration with a linker+E3 ligand.

It also develops V-body platform, a bispecifics, ADCs, CAR-T, and V-body-oligonucleotide conjugates. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023.

Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.

Valerio Therapeutics Société anonyme
CountryFrance
Founded1997
IndustryBiotechnology
SectorHealthcare
Employees19
CEOJulien Miara

Contact Details

Address:
49, boulevard du GEnEral Martial Valin
Paris, 75015
France
Phone33 1 45 58 76 00
Websitevaleriotx.com

Stock Details

Ticker SymbolALVIO
ExchangeEuronext Paris
Fiscal YearJanuary - December
Reporting CurrencyEUR
ISIN NumberFR0010095596
SIC Code2836

Key Executives

NamePosition
Antoine BaroukyDeputy Chief Executive Officer
Julien MiaraChief Executive Officer and Chairman
Joyce CareyExecutive Director of Finance and Head of FP&A
Robin SutherlandVice President and Global Head of Human Resources
Michel ForestChief Pharmacist and Quality Assurance Director
Huiping JiangSenior Vice President of Regulatory Affairs and Quality Assurance
Wael Jdey Ph.D.Head of Preclinical
Dr. Donna Cabral-Lilly Ph.D.Vice President and Head of CMC
Pam SlatcherHead of Global PV